Share Price and Basic Stock Data
Last Updated: January 23, 2026, 9:02 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Mangalam Drugs and Organics Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹77.8 Cr and a share price of ₹49.2. The company has experienced fluctuations in sales, reporting ₹372 Cr in sales for the fiscal year ending March 2023, a decline from ₹451 Cr in March 2022. The trailing twelve months (TTM) sales stood at ₹269 Cr, indicating a continued downward trend. Quarterly sales figures show a peak of ₹108.33 Cr in September 2022, followed by a gradual decline, with the most recent quarter ending September 2023 reporting sales of ₹81.56 Cr. This volatility in revenue could be attributed to various factors, including market competition, operational challenges, and potential disruptions in supply chains. The company’s revenue performance has not only been inconsistent but also lower than industry benchmarks, which typically exhibit more stable growth patterns.
Profitability and Efficiency Metrics
The profitability of Mangalam Drugs and Organics has been under pressure, as evidenced by its operating profit margin (OPM), which stood at -5.71% in the latest reported quarter. This contrasts sharply with its OPM of 7.79% in September 2022, highlighting a significant deterioration in operational efficiency. Net profit margins also reflect this trend, recording a net loss of ₹19 lakh for the fiscal year ending March 2025, with a net profit margin of 2.11% in the last reported year. The interest coverage ratio (ICR) stands at 2.43x, suggesting that the company can meet its interest obligations, but the declining profitability raises concerns about long-term sustainability. Additionally, the company’s return on equity (ROE) is relatively low at 4.71%, which is below the typical sector range, indicating that shareholder returns are not being maximized effectively.
Balance Sheet Strength and Financial Ratios
Mangalam Drugs and Organics reported total borrowings of ₹95 Cr against reserves of ₹112 Cr, resulting in a debt-to-equity ratio of 0.54x, which is moderate but indicates reliance on external financing. The company’s current ratio is 1.04, suggesting it can cover its short-term liabilities, while the quick ratio remains low at 0.31, indicating potential liquidity challenges. The book value per share has improved to ₹94.12, up from ₹85.79 in the previous fiscal year, reflecting a strengthening asset base. However, the cash conversion cycle (CCC) of 148 days indicates inefficiencies in managing working capital, particularly in inventory management, which stood at 303 days in March 2025. These figures reveal a mixed balance sheet where asset growth is overshadowed by liquidity and operational efficiency concerns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mangalam Drugs reveals a stable promoter holding of 50.30%, with public shareholders constituting 49.57% and foreign institutional investors (FIIs) holding a mere 0.11%. The number of shareholders has increased to 19,881, reflecting growing interest, albeit limited institutional backing. The consistent promoter stake suggests confidence in the company’s long-term strategy, but the low FII participation could indicate skepticism regarding growth prospects. The shift in public shareholding, with a slight reduction in percentage over recent quarters, may raise questions about market sentiment. Investor confidence could be further bolstered by improved operational performance and a clearer strategic direction, as the current low institutional interest may hinder broader market acceptance.
Outlook, Risks, and Final Insight
Looking ahead, Mangalam Drugs faces several challenges that could impact its operational viability. Key risks include ongoing profitability issues, as evidenced by consistent net losses and declining sales figures, which may deter potential investors. Additionally, the high cash conversion cycle presents a risk of liquidity constraints, particularly in a volatile economic environment. However, strengths such as a solid promoter stake and moderate leverage could provide stability. For the company to enhance its market position, it must focus on improving operational efficiencies, reducing costs, and engaging more actively with institutional investors. A turnaround in profitability paired with a strategic realignment could lead to a more favorable outlook, while failure to address these operational challenges may result in continued underperformance in a competitive sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 198/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 318 | 479/192 | 71.5 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,523.94 Cr | 1,087.19 | 47.42 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108.33 | 63.32 | 91.11 | 87.46 | 81.56 | 97.34 | 102.24 | 76.53 | 79.94 | 88.71 | 73.04 | 57.35 | 49.54 |
| Expenses | 99.89 | 56.84 | 90.87 | 90.94 | 79.37 | 90.36 | 90.54 | 68.34 | 71.25 | 79.94 | 62.88 | 61.86 | 52.37 |
| Operating Profit | 8.44 | 6.48 | 0.24 | -3.48 | 2.19 | 6.98 | 11.70 | 8.19 | 8.69 | 8.77 | 10.16 | -4.51 | -2.83 |
| OPM % | 7.79% | 10.23% | 0.26% | -3.98% | 2.69% | 7.17% | 11.44% | 10.70% | 10.87% | 9.89% | 13.91% | -7.86% | -5.71% |
| Other Income | 0.00 | 0.13 | 0.29 | 0.02 | 0.03 | 0.00 | 0.05 | 0.02 | 0.14 | 0.13 | 0.21 | 0.00 | 0.03 |
| Interest | 2.56 | 3.22 | 3.43 | 3.41 | 3.24 | 3.31 | 3.95 | 3.75 | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 |
| Depreciation | 2.76 | 2.88 | 2.75 | 3.42 | 3.73 | 3.62 | 3.86 | 3.87 | 3.97 | 3.93 | 4.61 | 4.38 | 4.53 |
| Profit before tax | 3.12 | 0.51 | -5.65 | -10.29 | -4.75 | 0.05 | 3.94 | 0.59 | 1.19 | 1.48 | 1.73 | -12.93 | -12.36 |
| Tax % | 28.85% | 15.69% | -22.30% | -7.29% | -25.05% | -920.00% | 9.90% | -355.93% | -125.21% | 5.41% | 90.75% | 6.19% | -41.42% |
| Net Profit | 2.23 | 0.43 | -4.39 | -9.54 | -3.56 | 0.50 | 3.55 | 2.68 | 2.69 | 1.40 | 0.15 | -13.73 | -7.25 |
| EPS in Rs | 1.41 | 0.27 | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 | -4.58 |
Last Updated: December 30, 2025, 1:37 am
Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 49.54 Cr.. The value appears to be declining and may need further review. It has decreased from 57.35 Cr. (Jun 2025) to 49.54 Cr., marking a decrease of 7.81 Cr..
- For Expenses, as of Sep 2025, the value is 52.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 61.86 Cr. (Jun 2025) to 52.37 Cr., marking a decrease of 9.49 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.83 Cr.. The value appears strong and on an upward trend. It has increased from -4.51 Cr. (Jun 2025) to -2.83 Cr., marking an increase of 1.68 Cr..
- For OPM %, as of Sep 2025, the value is -5.71%. The value appears strong and on an upward trend. It has increased from -7.86% (Jun 2025) to -5.71%, marking an increase of 2.15%.
- For Other Income, as of Sep 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 5.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.04 Cr. (Jun 2025) to 5.03 Cr., marking an increase of 0.99 Cr..
- For Depreciation, as of Sep 2025, the value is 4.53 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.38 Cr. (Jun 2025) to 4.53 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Sep 2025, the value is -12.36 Cr.. The value appears strong and on an upward trend. It has increased from -12.93 Cr. (Jun 2025) to -12.36 Cr., marking an increase of 0.57 Cr..
- For Tax %, as of Sep 2025, the value is -41.42%. The value appears to be improving (decreasing) as expected. It has decreased from 6.19% (Jun 2025) to -41.42%, marking a decrease of 47.61%.
- For Net Profit, as of Sep 2025, the value is -7.25 Cr.. The value appears strong and on an upward trend. It has increased from -13.73 Cr. (Jun 2025) to -7.25 Cr., marking an increase of 6.48 Cr..
- For EPS in Rs, as of Sep 2025, the value is -4.58. The value appears strong and on an upward trend. It has increased from -8.67 (Jun 2025) to -4.58, marking an increase of 4.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:00 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 269 |
| Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 257 |
| Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 12 |
| OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% | 4% |
| Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 17 |
| Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -22 |
| Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | |
| Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -19 |
| EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -12.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 300.00% | 166.67% | 37.50% | -9.09% | -140.00% | 200.00% | 250.00% | -28.57% | -95.00% | -1000.00% | 177.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -129.17% | -46.59% | -130.91% | 340.00% | 50.00% | -278.57% | -66.43% | -905.00% | 1177.78% |
Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 1:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 112 |
| Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 95 |
| Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 87 |
| Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
| Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 152 |
| CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 |
| Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 155 |
| Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 95.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 96.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 87.00 Cr.. The value appears to be improving (decreasing). It has decreased from 114.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 27.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 310.00 Cr.. The value appears to be improving (decreasing). It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 152.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 152.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 155.00 Cr.. The value appears to be declining and may need further review. It has decreased from 201.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 46.00 Cr..
- For Total Assets, as of Sep 2025, the value is 310.00 Cr.. The value appears to be declining and may need further review. It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
Notably, the Reserves (112.00 Cr.) exceed the Borrowings (95.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -67.00 | -58.00 | -22.00 | -19.00 | -22.00 | -55.00 | -28.00 | -17.00 | -39.00 | -63.00 | -90.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
| Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
| Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
| Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
| Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
| ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.25 | -5.73 |
| Diluted EPS (Rs.) | 4.25 | -5.73 |
| Cash EPS (Rs.) | 14.74 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Revenue From Operations / Share (Rs.) | 201.05 | 232.87 |
| PBDIT / Share (Rs.) | 22.95 | 11.05 |
| PBIT / Share (Rs.) | 12.46 | 1.80 |
| PBT / Share (Rs.) | 3.02 | -7.00 |
| Net Profit / Share (Rs.) | 4.25 | -5.73 |
| NP After MI And SOA / Share (Rs.) | 4.25 | -5.73 |
| PBDIT Margin (%) | 11.41 | 4.74 |
| PBIT Margin (%) | 6.19 | 0.77 |
| PBT Margin (%) | 1.50 | -3.00 |
| Net Profit Margin (%) | 2.11 | -2.46 |
| NP After MI And SOA Margin (%) | 2.11 | -2.46 |
| Return on Networth / Equity (%) | 4.51 | -6.68 |
| Return on Capital Employeed (%) | 11.27 | 1.67 |
| Return On Assets (%) | 1.83 | -2.71 |
| Long Term Debt / Equity (X) | 0.06 | 0.09 |
| Total Debt / Equity (X) | 0.54 | 0.64 |
| Asset Turnover Ratio (%) | 0.90 | 0.00 |
| Current Ratio (X) | 1.04 | 1.07 |
| Quick Ratio (X) | 0.31 | 0.31 |
| Inventory Turnover Ratio (X) | 2.43 | 0.00 |
| Interest Coverage Ratio (X) | 2.43 | 1.26 |
| Interest Coverage Ratio (Post Tax) (X) | 1.45 | 0.34 |
| Enterprise Value (Cr.) | 196.06 | 233.41 |
| EV / Net Operating Revenue (X) | 0.61 | 0.63 |
| EV / EBITDA (X) | 5.40 | 13.34 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.39 |
| Price / BV (X) | 0.78 | 1.08 |
| Price / Net Operating Revenue (X) | 0.36 | 0.39 |
| EarningsYield | 0.05 | -0.06 |
After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 3.52 (Mar 24) to 14.74, marking an increase of 11.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 201.05. It has decreased from 232.87 (Mar 24) to 201.05, marking a decrease of 31.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 22.95. This value is within the healthy range. It has increased from 11.05 (Mar 24) to 22.95, marking an increase of 11.90.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.46. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 12.46, marking an increase of 10.66.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has increased from -7.00 (Mar 24) to 3.02, marking an increase of 10.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 4.74 (Mar 24) to 11.41, marking an increase of 6.67.
- For PBIT Margin (%), as of Mar 25, the value is 6.19. This value is below the healthy minimum of 10. It has increased from 0.77 (Mar 24) to 6.19, marking an increase of 5.42.
- For PBT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has increased from -3.00 (Mar 24) to 1.50, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 5. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 8. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 15. It has increased from -6.68 (Mar 24) to 4.51, marking an increase of 11.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 11.27, marking an increase of 9.60.
- For Return On Assets (%), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 1.83, marking an increase of 4.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 0.64 (Mar 24) to 0.54, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.00 (Mar 24) to 0.90, marking an increase of 0.90.
- For Current Ratio (X), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.04, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.31.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.43, marking an increase of 2.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 2.43, marking an increase of 1.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 0.34 (Mar 24) to 1.45, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 196.06. It has decreased from 233.41 (Mar 24) to 196.06, marking a decrease of 37.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.61, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 5.40. This value is within the healthy range. It has decreased from 13.34 (Mar 24) to 5.40, marking a decrease of 7.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For Price / BV (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.08 (Mar 24) to 0.78, marking a decrease of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to 0.05, marking an increase of 0.11.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
- Net Profit Margin: 2.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.27% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.51% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.45
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 47.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Rupam Building, 3rd Floor, Mumbai Maharashtra 400001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Govardhan Murlidhar Dhoot | Chairman & Managing Director |
| Mr. Brijmohan Murlidhar Dhoot | Whole Time Director |
| Mr. Praveen Saxena | Independent Director |
| Mr. Rakesh Kishinchand Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh Prabhukumar Dhandhania | Independent Director |
| Mrs. Nidhi Shantanu Mundada | Independent Director |
FAQ
What is the intrinsic value of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's intrinsic value (as of 23 January 2026) is ₹24.25 which is 45.38% lower the current market price of ₹44.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹70.2 Cr. market cap, FY2025-2026 high/low of ₹123/22.7, reserves of ₹112 Cr, and liabilities of ₹310 Cr.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 70.2 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 23 January 2026?
The current stock price of Mangalam Drugs and Organics Ltd as on 23 January 2026 is ₹44.4.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is ₹123/22.7.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 80.5.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 8.03 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 4.71 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.